DANONE (BSN.DE) Stock Fundamental Analysis
FRA:BSN - Deutsche Boerse Ag - FR0000120644 - Common Stock - Currency: EUR
We assign a fundamental rating of 5 out of 10 to BSN. BSN was compared to 57 industry peers in the Food Products industry. BSN scores excellent on profitability, but there are concerns on its financial health. While showing a medium growth rate, BSN is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year BSN was profitable.
In the past year BSN had a positive cash flow from operations.
Each year in the past 5 years BSN has been profitable.
Each year in the past 5 years BSN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.46%, BSN is in the better half of the industry, outperforming 64.91% of the companies in the same industry.
BSN has a better Return On Equity (11.34%) than 70.18% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.58%, BSN is in the better half of the industry, outperforming 63.16% of the companies in the same industry.
BSN had an Average Return On Invested Capital over the past 3 years of 6.38%. This is in line with the industry average of 6.38%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.46% | ||
| ROE | 11.34% | ||
| ROIC | 6.58% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
BSN has a better Profit Margin (7.37%) than 75.44% of its industry peers.
In the last couple of years the Profit Margin of BSN has remained more or less at the same level.
With a decent Operating Margin value of 13.00%, BSN is doing good in the industry, outperforming 78.95% of the companies in the same industry.
In the last couple of years the Operating Margin of BSN has declined.
BSN has a Gross Margin of 49.70%. This is in the better half of the industry: BSN outperforms 70.18% of its industry peers.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13% | ||
| PM (TTM) | 7.37% | ||
| GM | 49.7% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
BSN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BSN has been reduced compared to 5 years ago.
Compared to 1 year ago, BSN has an improved debt to assets ratio.
2.2 Solvency
BSN has an Altman-Z score of 2.43. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
BSN's Altman-Z score of 2.43 is in line compared to the rest of the industry. BSN outperforms 59.65% of its industry peers.
The Debt to FCF ratio of BSN is 4.89, which is a neutral value as it means it would take BSN, 4.89 years of fcf income to pay off all of its debts.
BSN's Debt to FCF ratio of 4.89 is fine compared to the rest of the industry. BSN outperforms 70.18% of its industry peers.
A Debt/Equity ratio of 0.66 indicates that BSN is somewhat dependend on debt financing.
BSN has a Debt to Equity ratio (0.66) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 4.89 | ||
| Altman-Z | 2.43 |
ROIC/WACC1.05
WACC6.25%
2.3 Liquidity
A Current Ratio of 0.93 indicates that BSN may have some problems paying its short term obligations.
BSN has a Current ratio of 0.93. This is in the lower half of the industry: BSN underperforms 78.95% of its industry peers.
BSN has a Quick Ratio of 0.93. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
BSN's Quick ratio of 0.77 is on the low side compared to the rest of the industry. BSN is outperformed by 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.54%.
The Earnings Per Share has been decreasing by -1.17% on average over the past years.
The Revenue has decreased by -0.88% in the past year.
The Revenue has been growing slightly by 1.60% on average over the past years.
EPS 1Y (TTM)2.54%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%2.81%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%1.24%
3.2 Future
Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 5.97% on average per year.
BSN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.42% yearly.
EPS Next Y7.96%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
EPS Next 5Y5.97%
Revenue Next Year1.76%
Revenue Next 2Y2.51%
Revenue Next 3Y2.9%
Revenue Next 5Y3.42%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 19.82, BSN is valued on the expensive side.
The rest of the industry has a similar Price/Earnings ratio as BSN.
BSN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.34.
BSN is valuated rather expensively with a Price/Forward Earnings ratio of 18.36.
BSN's Price/Forward Earnings is on the same level as the industry average.
BSN's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 22.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.82 | ||
| Fwd PE | 18.36 |
4.2 Price Multiples
BSN's Enterprise Value to EBITDA is on the same level as the industry average.
BSN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.86 | ||
| EV/EBITDA | 10.7 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)2.49
PEG (5Y)N/A
EPS Next 2Y7.64%
EPS Next 3Y7.59%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.94%. Purely for dividend investing, there may be better candidates out there.
BSN's Dividend Yield is a higher than the industry average which is at 3.19.
BSN's Dividend Yield is a higher than the S&P500 average which is at 2.40.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.94% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
BSN pays out 66.80% of its income as dividend. This is not a sustainable payout ratio.
The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP66.8%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
FRA:BSN (6/18/2025, 7:00:00 PM)
71.96
+0.2 (+0.28%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners48.65%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap49.01B
Analysts72.5
Price Target75.19 (4.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.94% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP66.8%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.12%
PT rev (3m)3.61%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.82 | ||
| Fwd PE | 18.36 | ||
| P/S | 1.79 | ||
| P/FCF | 16.86 | ||
| P/OCF | 12.8 | ||
| P/B | 2.75 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.7 |
EPS(TTM)3.63
EY5.04%
EPS(NY)3.92
Fwd EY5.45%
FCF(TTM)4.27
FCFY5.93%
OCF(TTM)5.62
OCFY7.81%
SpS40.2
BVpS26.13
TBVpS-9.13
PEG (NY)2.49
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.46% | ||
| ROE | 11.34% | ||
| ROCE | 11.27% | ||
| ROIC | 6.58% | ||
| ROICexc | 8.06% | ||
| ROICexgc | 68% | ||
| OM | 13% | ||
| PM (TTM) | 7.37% | ||
| GM | 49.7% | ||
| FCFM | 10.62% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexcg growth 3Y19.7%
ROICexcg growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 4.89 | ||
| Debt/EBITDA | 2.49 | ||
| Cap/Depr | 79.02% | ||
| Cap/Sales | 3.37% | ||
| Interest Coverage | 20.69 | ||
| Cash Conversion | 81.04% | ||
| Profit Quality | 144.05% | ||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 2.43 |
F-Score7
WACC6.25%
ROIC/WACC1.05
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)2.54%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%2.81%
EPS Next Y7.96%
EPS Next 2Y7.64%
EPS Next 3Y7.59%
EPS Next 5Y5.97%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%1.24%
Revenue Next Year1.76%
Revenue Next 2Y2.51%
Revenue Next 3Y2.9%
Revenue Next 5Y3.42%
EBIT growth 1Y2.24%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.65%
EBIT Next 3Y14.25%
EBIT Next 5Y11.14%
FCF growth 1Y11.98%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y11.24%
OCF growth 3Y3.31%
OCF growth 5Y2.15%